News
Pfizer beats in Q2 earnings, reaffirms 2025 outlook
Pfizer ( PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 billion in revenues. The company reported revenues of $14.7 billion, compared to Wall Street expectations of $13.5 billion, and earnings per share of $0.78, versus estimates of $0.58 per share.
In the second quarter, Pfizer reported adjusted diluted earnings per share of $0.78 on revenue of nearly $14.7 billion. Both ...
Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...
Pfizer CEO Albert Bourla is expected at a pro-Trump fundraiser on Friday, sources told CBS News, one day after the president ...
Pfizer boosted its profit outlook for the year following gains to its top- and bottom-line in its latest quarter.
Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...
CEO says pharma executives discussed Trump's call to launch DTC initiatives under his Most Favored Nation policy to lower U.S ...
Pfizer ( PFE) CEO Albert Bourla said Tuesday he has a "special relationship" with President Trump, cemented during the ...
Pfizer's Albert Bourla told investors that major drugmakers are "ready to roll up their sleeves" and build out more direct-to ...
Pfizer stock rose after the drugmaker posted adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback